CytoVas LLC is a life science company with a unique computationally-enabled cell and extracellular vesicle-based platform that is advancing precision medicine by providing clinicians and drug developers with actionable information on novel cellular markers of disease progression and individual treatment response. The company’s technology uniquely enables it to discover and mine flow cytometry data to rapidly identify and automate interpretation of novel cellular biomarkers. This breakthrough approach enables clients to make critical decisions in their efforts to develop and deliver safer, more precisely targeted therapies for patients. The evPREDICT™ and CLOUD CYTOMICS™ platforms are broadly applicable across therapeutic areas and disease states and used throughout all stages of drug development. CytoVas is currently working with partners to exploit the technology’s potential in Cardiovascular Disease, Type 2 Diabetes, Preeclampsia, Alzheimer’s, Acute Myeloid Leukemia, Psoriasis, Rheumatoid Arthritis, Traumatic Brain Injury, Acute Heart Failure, Chronic Kidney Disease, Transplant Rejection, and Peripheral Arterial Disease. Founded by world-renowned experts in computational biology, flow cytometry and cardiology at the Perelman School of Medicine at the University of Pennsylvania, the Company is led today by an experienced management team and scientific advisory board with a track record of success. Privately held as a part of the Pennovation initiative, CytoVas has been funded by primary investments from the American Heart Association, the National Institutes of Health and the University of Pennsylvania, and a partnership with Becton Dickinson Biosciences, a world leader in flow cytometry.